Commercial Strategies

In a competitive immunology landscape, Eli Lilly is looking for novel agents, oral formulations of injectables, and combination therapies that can optimize response and expand the patient pool.

The early adoption of artificial intelligence/machine learning has centered around drug discovery, but the technologies are being applied to other fields, including pharma marketing.

GLP-1 drugs like Ozempic and Mounjaro have shaken up pharma, crossing firmly over into the mainstream while netting fortunate suppliers billions of dollars in the process. As patent expiry approaches for first- and second-generation products, generics manufacturers are gearing up to take a share of the spoils.

As the pharmaceutical industry readies itself to navigate the complexities of 2025, US pricing trends reveal a landscape shaped by regulatory and legislative changes, innovative pricing models, and the ongoing impact of inflation.

Octave Bioscience’s CEO Doug Biehn sat down with Medtech Insight at HLTH to talk about the company’s plans for expanding their multivariate biomarker blood test for MS analysis and development of a diagnostic for Parkinson’s disease.

Despite the importance of developing and commercializing new products to fuel pharma revenue growth, it is estimated that approximately up to 50% of drug launches fail to meet financial expectations. We explore how to maximize product success in pharma's value era.

Since taking on the CEO role at Theratechnologies in 2020, Paul Lévesque has made it his priority to beef up the company’s commercial portfolio and look for partnerships on potentially high-value programs. Now, the Canadian biotech is turning a profit for the first time in many years.

CEO of Sumitomo Pharma America unit, Adele M. Gulfo, draws from experiences working across companies including Pfizer, to advise on go-to-market strategies for a portfolio across primary care to rare disease.

Germany’s Medical Research Act clears its final legal hurdle after federal council sign off.